Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

900P - AI-powered analyzer reveals enrichment of intra-tumoral tumor-infiltrating lymphocytes in high-grade neuroendocrine neoplasms

Date

10 Sep 2022

Session

Poster session 10

Topics

Tumour Immunology

Tumour Site

Neuroendocrine Neoplasms

Presenters

Hyung-Gyo Cho

Citation

Annals of Oncology (2022) 33 (suppl_7): S410-S416. 10.1016/annonc/annonc1060

Authors

H. Cho1, S. Kim2, S. Choi3, S.I. Cho1, W. Jung1, S. Kim1, G. Park4, S. Song1, S. Pereira1, H. Song1, S. Park1, M. Mostafavi1, K. Paeng1, C. Ock1

Author affiliations

  • 1 Oncology, Lunit, 06241 - Seoul/KR
  • 2 Department Of Pathology, Ajou University School of Medicine, 443-721 - Suwon/KR
  • 3 Pathology, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 4 Oncology, Lunit, 6247 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 900P

Background

The efficacy of immune checkpoint inhibitors (ICIs) in neuroendocrine neoplasms (NEN) has not been fully explored, but recent clinical trials showed the effectiveness of ICIs in high-grade NEN. Despite the importance of tumor-infiltrating lymphocytes (TIL) and PD-L1 expression to ICI treatment outcomes, a comprehensive assessment of these biomarkers has not yet been conducted in NEN. We investigated PD-L1 expression and TIL distributions in NENs using an artificial intelligence (AI)-powered analyzer.

Methods

A total of 218 NEN cases were obtained from Ajou University Medical Center in Korea from 2020 to 2021. Primary sites include colorectum (N=158), small intestine (N=16), stomach (N=15), hepatopancreatobiliary (N=15), lung (N=7), and other organs (N=7). Low/intermediate grade NEN (neuroendocrine tumor [NET] G1/G2) and high grade NEN (NET G3 or neuroendocrine carcinoma) were 190 and 28, respectively. TIL distribution was derived from Lunit SCOPE IO, an AI-powered H&E analyzer, which was developed from 17,849 H&E WSI. Two pathologists interpreted the combined positive score (CPS) of PD-L1 22C3-stained slides.

Results

The proportion of intratumoral TIL high cases (upper than median TIL density) was higher in high grade NEN (75% vs 46%, P<0.01, Odds ratio 3.477 [IQR: 1.393 – 9.148]). Stromal TIL and combined (intratumoral and stromal) TIL densities showed insignificant differences between histologic groups. The proportion of PD-L1 CPS ≥ 1 cases was higher in high grade NEN (85% vs 33%, P < 0.0001, Odds ratio 12.1 [IQR: 4.169 – 33.15]). The PD-L1 CPS ≥ 1 group showed significantly higher intratumoral, stromal, and combined TIL densities compared to the CPS < 1 group (7.13 vs 2.95, P < 0.0001; 200.9 vs 120.5, P < 0.001; 86.7 vs 56.1, P<0.01). A significant correlation was observed between TIL density and PD-L1 CPS (r=0.37, P<0.0001 for intratumoral TIL; r=0.24, P<0.01 for stromal TIL and combined TIL).

Conclusions

AI-powered TIL analysis reveals that intra-tumoral TIL density is significantly higher in high grade NEN, and PD-L1 CPS has a positive correlation with TIL densities. Thus, AI-powered TIL analysis and PD-L1 CPS can be investigated as predictive biomarkers for ICI response in NEN.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Lunit Inc.

Funding

Lunit Inc.

Disclosure

H. Cho, W. Jung, S. Kim, G. Park, S. Song, S. Pereira, S. Park, M. Mostafavi, K. Paeng: Financial Interests, Personal, Full or part-time Employment: Lunit Inc. S.I. Cho: Financial Interests, Personal, Full or part-time Employment: Lunit Inc.; Financial Interests, Personal, Stocks/Shares: Lunit Inc. H. Song: Financial Interests, Personal, Ownership Interest: Lunit Inc. C. Ock: Financial Interests, Personal, Full or part-time Employment: Lunit Inc.; Financial Interests, Personal, Invited Speaker: Ybiologics; Financial Interests, Personal, Stocks/Shares: Lunit Inc., Ybiologics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.